Thursday, October 15, 2026

BTC $80,544 ▼ 1.27%

NewsLive Wire Politics World Markets Digital Assets Technology Sports

FranchisesThe Brief The Big Read The Breakdown Crypto Culture

MoreDeFi & On-Chain U.S. Equities Macro & Rates Research

LIVE

ADA$0.220−4.33%ETH$2,350−2.85%LINK$12.00−3.42%SOL$101.72−2.37%BTC$80,544−1.27%XRP$1.30−2.53%S&P 5007,719−1.11%Nasdaq26,693−1.88%Dow51,621−0.09%RUT2,730−1.93%TNX5.19%−0.52%TYX5.53%−0.68%FVX4.99%−0.30%IRX4.08%+0.69%VIX16.87+10.48%GOLD$4,158.50+1.23%SILVER$56.06+0.32%OIL$94.07−1.07%DXY102.07−0.47%NVDA$221.30−3.16%AAPL$342.96+0.50%TSLA$367.16−2.15%META$737.54−3.27%MSFT$533.69−1.80%AMZN$254.08−1.74%GOOGL$347.64−1.74%Fear & Greed53 — NeutralADA$0.220−4.33%ETH$2,350−2.85%LINK$12.00−3.42%SOL$101.72−2.37%BTC$80,544−1.27%XRP$1.30−2.53%S&P 5007,719−1.11%Nasdaq26,693−1.88%Dow51,621−0.09%RUT2,730−1.93%TNX5.19%−0.52%TYX5.53%−0.68%FVX4.99%−0.30%IRX4.08%+0.69%VIX16.87+10.48%GOLD$4,158.50+1.23%SILVER$56.06+0.32%OIL$94.07−1.07%DXY102.07−0.47%NVDA$221.30−3.16%AAPL$342.96+0.50%TSLA$367.16−2.15%META$737.54−3.27%MSFT$533.69−1.80%AMZN$254.08−1.74%GOOGL$347.64−1.74%Fear & Greed53 — Neutral

Tag

weight loss drugs

3 articles

U.S. Equities4d ago

Viking's Oral VK2735 Hits a Tolerability Wall; Injectable Offers the Real Upside

VKTX's oral weight-loss candidate shows efficacy but high discontinuation rates in Phase 2 trials. The injectable formulation is where the value lies heading into 2027 Phase 3 readout.

U.S. Equities83d ago

Eli Lilly's Retatrutide FDA Bid Targets $25B Peak Sales in $100B Obesity Market

Lilly's triple-receptor weight-loss drug retatrutide heads to FDA with a 24 percent efficacy edge over rivals and a $1,200 price target from JPMorgan.

U.S. Equities83d ago

Galderma CEO: 'Ozempic Face' Is Driving Real Filler Demand

Galderma's injectables business is gaining a new patient demographic as GLP-1 users seek treatments for facial volume loss.